New sources of drugs for hematologic malignancies

Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multitarget mechanism discovered through systematic combination screening in B-cell malignancies

(2010) R. J. Rickles et al.   BLOOD

Incentives for Drug Development — The Curious Case of Colchicine

(2010) Aaron S. Kesselheim et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells

(2009) Y. Eberhard et al.   BLOOD

Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin

(2009) S. Assouline et al.   BLOOD

The value of drug repositioning in the current pharmaceutical market

(2009) E.L. Tobinick   DRUG NEWS & PERSPECTIVES

Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML

(2008) Alison R. Walker et al.   LEUKEMIA RESEARCH